PHILADELPHIA and VANCOUVER, British Columbia — January 13, 2026 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) has announced an 11-month sustained complete resolution of lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS in a Phase 1/2a study.
The patient, who is hormone receptor-positive (HR+) and HER2-negative, experienced no treatment-limiting toxicities and maintained stable disease at all other evaluable sites.
The complete response was initially observed at 2 months, and subsequently confirmed at 4, 6, and now at 11 months.
The 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures received 17 cycles of Bria-OTS and completed 12 months of the study and remains in survival follow-up.
Bria-OTS is BriaCell’s personalized off-the-shelf immunotherapy.
The Phase 1 dose escalation portion of the study is complete, and the Phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor, is now underway.
Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study, stated the sustained clinical response observed in this late-stage MBC patient, who had previously progressed through multiple prior treatments is remarkable.
Dr. Chawla added that he is excited to further evaluate Bria-OTS in combination with an immune checkpoint inhibitor in metastatic breast cancer.
Dr. William V. Williams, BriaCell’s President and CEO, added these clinical findings reinforce confidence in the therapeutic potential and safety of the Bria-OTS platform.
BriaCell remains committed to advancing the novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options, according to Dr. Williams.
Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) in patients with metastatic recurrent breast cancer.
The trial includes both monotherapy dose escalation and checkpoint inhibitor combination dose expansion cohorts, and the company has recently entered the dose expansion phase.
Contact Information:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
Source: BriaCell Therapeutics Corp.
